Small Molecule Development & Manufacturting at Quotient Sciences

From Bench to Bedside: Accelerating from Preclinical to POC with a Truly Integrated development partner

Cambridge, United States | 19 March 2026
Overview

From Bench to Bedside: Accelerating from Preclinical to POC with a Truly Integrated development partner

This seminar explores the critical transition of a new drug from candidate nomination through to proof-of-concept studies, highlighting the scientific and operational strategies that drive successful early-phase programs.

The opening presentation explores the transition to first-in-human (FIH) studies, highlighting the role of predictive modelling in risk assessment, solubility profiling, and formulation screening. Real-world examples from Quotient demonstrate how these approaches enable more informed decision making to advance drug candidates into clinical development.

Following this, the seminar addresses formulation selection and drug product supply strategies, for the first-in-human and initial patient studies. The session discusses the implementation of innovative drug development strategies, supported by real-world examples of Translational Pharmaceutics in accelerating the journey from FIH to PoC. It explores how integrated patient supply solutions—like adaptive manufacturing processes that ensure rapid clinical supply changes—can streamline program execution and enhance flexibility throughout early clinical trials.

What distinguishes this seminar is exclusive access to industry experts and innovative methodologies. Interactive Q&A sessions with leading scientists from Quotient Sciences provide attendees with direct insights and practical solutions to common early-phase challenges. By blending expert guidance with actionable case studies, the event offers a unique opportunity to optimize molecule readiness and delivery in early clinical development.

Learning objectives:

  • Understand the key scientific and operational considerations in transitioning from preclinical to first-in-human (FIH) studies
  • Identify formulation strategies and drug product types suitable for FIH programs, and how these influence clinical flexibility and patient outcomes.
  • Gain insight into Quotient’s integrated services, including Translational Pharmaceutics, and how they streamline formulation development and patient supply.
     
TimeDescription
11:30 AM - 12:15 PMRegistration, networking (lunch buffet will be open)
12:15 PM – 1:00 PMPresentation by Vanessa
1:00 PM - 1:15 PMQ&A
1:15 PM - onwardsNetworking after the session

Space is limited! Register your interest to attend our seminar. If you have any questions or difficulty registering, reach out to [email protected].

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register
Location
MassBio (Massachusetts Biotechnology Council)
700 Technology Square, 5th Floor, MA 02139
Cambridge, United States

Meet our expert:

We look forward to meeting you at the seminar.

Dr. Vanessa Zann

VP, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA

Dr. Vanessa Zann has over twenty-five years industry experience providing expert biopharmaceutic support to drug discovery, early ...

About Vanessa

Learn more about Translational Pharmaceutics:

Read more
Translational Pharmaceutics®, Articles & Publications, News & Announcements John McDermott Contributes to European Pharmaceutical Manufacturer By: John McDermott
Learn More
Translational Pharmaceutics®, Thierry Van Nieuwenhove Video Interview with BioPharm International: Integrated Services for the Whole Drug Development Pathway By: Thierry Van Nieuwenhove
Learn More
Translational Pharmaceutics®, Formulation Development, Clinical Trials John McDermott, Dr. Andrew Parker, and Dr. Sandeep Kumar featured in Drug Development & Delivery
Learn More